Find the best industry partner and maximize the value of your drug research. Learn how at our website to advance their research, but the license agreement only a fraction of the drugs that universities have long sought partnerships with industry partners.

Who has been successful in the race to treat disease areas?

Top drug development per region

<table>
<thead>
<tr>
<th>Region</th>
<th>Number of Deals</th>
</tr>
</thead>
<tbody>
<tr>
<td>North America</td>
<td>2015 - 2019</td>
</tr>
<tr>
<td>Asia-Pacific</td>
<td>2015 - 2019</td>
</tr>
<tr>
<td>Europe</td>
<td>2015 - 2019</td>
</tr>
<tr>
<td>Latin America</td>
<td>2015 - 2019</td>
</tr>
</tbody>
</table>

Drug development and clinical trials

- **Solid tumor**: Focal and branched chain fatty acid synthesis
- **Glioblastoma**: A drug for patients.
- **Alzheimer's disease**: A drug for patients.
- **Cancer**: A drug for patients.
- **Diabetes**: A drug for patients.
- **Liver disease**: A drug for patients.
- **Heart disease**: A drug for patients.
- **Neurological disorders**: A drug for patients.
- **Infectious diseases**: A drug for patients.

- **52%**
- **45%**
- **17%**
- **17%**
- **8%**

Global deal count by dollar

- **$15.8B**
- **$5.59B**
- **$235K**

- **5.36%**
- **1.34%**
- **0.15%**

The top deal makers per year for the last five years

- **$348.9M**
- **$291.1M**
- **$334.7M**
- **$268.8M**
- **$269.8M**

The top funding sources per dollar

- **$1.38M**
- **$1M**
- **$1.15M**
- **$1.33M**
- **$1.28M**

The top deal makers per dollar

- **$1.15M**
- **$1M**
- **$1.33M**
- **$1.34M**
- **$1.35M**

A closer look at the data

- **$5.36%**
- **1.34%**
- **0.15%**

Clarivate.com/academia